default author photo

Stefano Russconi

University of Milan - DIBIC “Luigi Sacco”

SCHOLARLY PAPERS

2

DOWNLOADS

100

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Switch to Dolutegravir/Rilpivirine in Virologically Suppressed, Antiretroviral Treatment-Experienced HIV-1 Infected Individuals with K103N Mutation: 48-Week Results of a Randomised, Pilot Clinical Trial

Number of pages: 23 Posted: 11 May 2023
Government of the United Kingdom - Chelsea and Westminster Hospital NHS Foundation Trust, Sorbonne University - Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Université de Paris Cité - AP-HP, King’s College Hospital NHS Foundation Trust, Hospital Universitari Vall d’Hebron, University of Milan - DIBIC “Luigi Sacco”, Université Libre de Bruxelles (ULB) - CHU Saint-Pierre, Goethe University Frankfurt - University Hospital Frankfurt, Centre Hospitalier Universitaire de Nantes, Government of the United Kingdom - Royal Free London NHS Foundation Trust, Universidad Miguel Hernández de Elche, University of Sussex - Brighton and Sussex Medical School, ViiV Healthcare Ltd., GSK plc, Research Organisation (KC) LTD, Research Organisation (KC) LTD, Research Organisation (KC) LTD, Government of the United Kingdom - Chelsea and Westminster Hospital NHS Foundation Trust and Independent
Downloads 70 (875,328)

Abstract:

Loading...

dolutegravir/rilpivirine, switch, virological suppression, adverse event, K103N mutation

2.

In vitro Characterization of Peptidomimetic Proteolysis Targeting Chimera (PROTAC) as a Degrader of 3-Chymotrypsin-Like Protease (Mpro/3CLpro) against SARS-CoV-2

Number of pages: 10 Posted: 04 Nov 2025
affiliation not provided to SSRN, Università degli Studi di Milano, University of Milan, Università degli Studi di Milano, affiliation not provided to SSRN, Università degli Studi di Milano, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and University of Milan - DIBIC “Luigi Sacco”
Downloads 30 (1,332,057)

Abstract:

Loading...

SARS-CoV2, Protease inhibitors, PROTAC, In vitro